RA Capital Management ACET Position
Active6-Fund ConvergenceRA Capital Management trimmed their position in Adicet Bio, Inc. (ACET) in Q4 2025, holding $8.0M worth of shares across 948,249 shares.
The position was first reported in Q2 2024 and has been tracked across 7 quarterly 13F filings.
ACET is a convergence signal: 6 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Adicet Bio, Inc.
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Full company profile →Short Interest
7.9%
4.7 days to cover
RA Capital Management ACET Position History
Frequently Asked Questions
Does RA Capital Management own ACET?
Yes. As of Q4 2025, RA Capital Management holds 948,249 shares of Adicet Bio, Inc. (ACET) valued at $8.0M. This data comes from their SEC 13F filing.
How many hedge funds own ACET?
6 specialist biotech hedge funds currently hold ACET, including OrbiMed Advisors, RTW Investments, EcoR1 Capital and 2 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did RA Capital Management first buy ACET?
RA Capital Management's position in ACET was first reported in Q2 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is RA Capital Management's ACET position increasing or decreasing?
RA Capital Management trimmed their ACET position in the most recent quarter, reducing by 6,592,751 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ACETCompany Page →
All fund holders, insider trades, catalysts, and cash runway
RA Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →